Utilizing Real-World Data To Advance Benign Prostatic Hyperplasia Research

By Jennifer Bepple, MD, MMCi

Benign prostatic hyperplasia (BPH) significantly impacts quality of life and healthcare use for millions of aging men across the world. Traditional clinical trials, while essential, often struggle to capture the full complexity of BPH’s progression in real-world settings. Real-world data (RWD) bridges this gap by offering longitudinal insights from patients. Verana Health leverages the American Urological Association Quality Registry, using advanced AI methods to develop a curated dataset of 1.7 million de-identified patients with rich follow-up data. This enables deeper phenotypic understanding, improved patient stratification, and the use of external control arms for clinical trials.

By integrating structured, semi-structured and unstructured data, RWD reveals nuanced insights into symptom progression, treatment response, and long-term outcomes. The use of RWD in BPH research not only enhances trial design and therapeutic development but also helps identify unmet needs and improve patient care. As BPH treatment continues to advance, the strategic use of real-world evidence will be crucial in driving innovation and shaping personalized care pathways.